Long-term investments in top tech, health, and consumer staples for stability, growth, and reliable returns. Read what ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...

Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024. Net sales for the quarter totaled 85.7 billion Danish kroner ($12 billion) and ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...